Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 277

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Open access
Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., Böckle, B. C., Caproni, M., Caux, F., Chandran, N.S., Cianchini, G., Daneshpazhooh, M., De, D., Didona, D., Di Zenzo, G. M., Dmochowski, M., Drenovska, K., Ehrchen, J., Goebeler, M., Groves, R., Günther, C., Horvath, B., Hertl, M., Hofmann, S., Ioannides, D., Itzlinger‐Monshi, B., Jedličková, J., Kowalewski, C., Kridin, K., Lim, Y. L., Marinovic, B., Marzano, A. V., Mascaro, J.‐M., Meijer, J.M., Murrell, D., Patsatsi, K., Pincelli, C., Prost, C., Rappersberger, K., Sárdy, M., Setterfield, J., Shahid, M., Sprecher, E., Tasanen, K., Uzun, S., Vassileva, S., Vestergaard, K., Vorobyev, A., Vujic, I., Wang, G., Wozniak, K., Yayli, S., Zambruno, G., Zillikens, D., Schmidt, E., Joly, P. · 2022 · Journal of the European Academy of Dermatology and Venereology

Abstract

Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo‐like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence‐based or rely on expert opinion. The degree of consent among all task force members was included. Results: Treatment depends on the severity of BP and patients' comorbidities. High‐potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B‐cell‐depleting therapy and intravenous immunoglobulins may be considered in treatment‐resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions: The guidelines for the management of BP were updated. They summarize evidence‐ and expert‐based recommendations useful in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.18220

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

Metadata

Authors
Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., Böckle, B. C., Caproni, M., Caux, F., Chandran, N. S., Cianchini, G., Daneshpazhooh, M., De, D., Didona, D., Di Zenzo, G. M., Dmochowski, M., Drenovska, K., Ehrchen, J., Goebeler, M., Groves, R., Günther, C., Horvath, B., Hertl, M., Hofmann, S., Ioannides, D., Itzlinger‐Monshi, B., Jedličková, J., Kowalewski, C., Kridin, K., Lim, Y. L., Marinovic, B., Marzano, A. V., Mascaro, J. ‐., Meijer, J. M., Murrell, D., Patsatsi, K., Pincelli, C., Prost, C., Rappersberger, K., Sárdy, M., Setterfield, J., Shahid, M., Sprecher, E., Tasanen, K., Uzun, S., Vassileva, S., Vestergaard, K., Vorobyev, A., Vujic, I., Wang, G., Wozniak, K., Yayli, S., Zambruno, G., Zillikens, D., Schmidt, E., & Joly, P.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2022-06-29
Volume
36
Issue
10
Pages
1689-1704
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W4283722628
Cited by
277
References
25
FWCI
29.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.